Peloton Therapeutics presents promising data on PT2385, the first Inhibitor of HIF-2a for renal cell carcinoma
20 April 2015 | By Victoria White
Peloton presented promising preclinical data on PT2385, the first Inhibitor of HIF-2a for renal cell carcinoma, at AACR 2015...